Literature DB >> 30355757

Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.

Lin Wang1, Xi Cao1, Zhenzi Wang1, Yuhua Gao1, Juan Deng1, Xueen Liu2, Hui Zhuang2.   

Abstract

The purpose of this study was to explore the correlations of serum hepatitis B core-related antigen (HBcrAg) with intrahepatic Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and HBV total DNA in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients. Serum HBcrAg and other parameters, including HBV DNA, HBV RNA, HBeAg, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were quantitatively measured at baseline and follow-up time points. Intrahepatic HBV cccDNA and total DNA were quantitatively detected at baseline and 96 weeks. Grading of liver necroinflammation and staging of hepatic fibrosis were assessed at baseline and 96 weeks. Correlations between serum HBcrAg and other parameters were analyzed by Pearson's correlation analysis. The results showed that pretreatment HBcrAg correlated significantly with HBV total DNA levels (r = 0.328, P  = 0.003) in 82 CHB patients, and, after removing three outliers, with intrahepatic HBV cccDNA (r = 0.323, P  = 0.004; n = 79). Serum HBcrAg correlated better with HBV cccDNA in patients with lower levels of serum HBV DNA (stratified by 7 log IU/ml of HBV DNA; r = 0.656, P  = 0.003 versus r = -0.02, P = 0.866). Significant inverse correlations were found between HBcrAg and grade of liver necroinflammation (r = -0.245, P  = 0.037), stage of hepatic fibrosis (r = -0.360, P  = 0.002) at baseline. Serum HBcrAg presented significant correlation with intrahepatic HBV cccDNA in patients with HBeAg seroconversion at 96 weeks (r = 0.622, P  = 0.006). The decrease in HBcrAg showed significant correlation with the decrease in HBV cccDNA after 96-week NA therapy (r = 0.282, P  = 0.043). Serum HBcrAg also correlated significantly with other serum markers at baseline and 96 weeks of NA therapy. In conclusion, baseline HBcrAg and its decreased value were significantly correlated with the corresponding intrahepatic HBV cccDNA.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  HBV RNA; chronic hepatitis B; covalently closed circular DNA; hepatitis B core-related antigen; nucleos(t)ide analogues

Mesh:

Substances:

Year:  2019        PMID: 30355757      PMCID: PMC6322451          DOI: 10.1128/JCM.01303-18

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

Review 1.  Hepatitis B virus infection.

Authors:  Christian Trépo; Henry L Y Chan; Anna Lok
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

2.  Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation.

Authors:  Toshihisa Matsuzaki; Ichikawa Tatsuki; Masashi Otani; Motohisa Akiyama; Eisuke Ozawa; Satoshi Miuma; Hisamitsu Miyaaki; Naota Taura; Tomayoshi Hayashi; Sadayuki Okudaira; Mitsuhisa Takatsuki; Hajime Isomoto; Fuminao Takeshima; Susumu Eguchi; Kazuhiko Nakao
Journal:  J Gastroenterol Hepatol       Date:  2013-07       Impact factor: 4.029

3.  Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.

Authors:  Jie Wang; Tao Shen; Xiangbo Huang; G Renuka Kumar; Xiangmei Chen; Zhenzhen Zeng; Ruiyang Zhang; Ran Chen; Tong Li; Tianying Zhang; Quan Yuan; Pao-Chen Li; Qi Huang; Richard Colonno; Jidong Jia; Jinlin Hou; Malcolm A McCrae; Zhiliang Gao; Hong Ren; Ningshao Xia; Hui Zhuang; Fengmin Lu
Journal:  J Hepatol       Date:  2016-05-28       Impact factor: 25.083

Review 4.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-03-27

5.  Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma.

Authors:  Meirong Wang; Ning Qiu; Shichun Lu; Dianrong Xiu; Jianguo Yu; Xing Tai Wang; Fengmin Lu; Tong Li; Xueen Liu; Hui Zhuang
Journal:  J Med Virol       Date:  2012-11-20       Impact factor: 2.327

6.  Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D.

Authors:  B Maasoumy; S B Wiegand; J Jaroszewicz; B Bremer; P Lehmann; K Deterding; A Taranta; M P Manns; H Wedemeyer; D Glebe; M Cornberg
Journal:  Clin Microbiol Infect       Date:  2015-02-17       Impact factor: 8.067

7.  The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study.

Authors:  George Zacharakis; John Koskinas; Stamatia Kotsiou; Fevronia Tzara; Nikolaos Vafeiadis; Menelaos Papoutselis; Eustratios Maltezos; Eleftherios Sivridis; Kostantinos Papoutselis
Journal:  J Hepatol       Date:  2008-07-02       Impact factor: 25.083

8.  Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection.

Authors:  Danny Ka-Ho Wong; Yasuhito Tanaka; Ching-Lung Lai; Masashi Mizokami; James Fung; Man-Fung Yuen
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

9.  Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B.

Authors:  En-Qiang Chen; Shu Feng; Meng-Lan Wang; Ling-Bo Liang; Ling-Yun Zhou; Ling-Yao Du; Li-Bo Yan; Chuan-Min Tao; Hong Tang
Journal:  Sci Rep       Date:  2017-03-14       Impact factor: 4.379

10.  Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels.

Authors:  Yuk-Fai Lam; Wai-Kay Seto; Danny Wong; Ka-Shing Cheung; James Fung; Lung-Yi Mak; John Yuen; Chun-Kong Chong; Ching-Lung Lai; Man-Fung Yuen
Journal:  Clin Transl Gastroenterol       Date:  2017-10-26       Impact factor: 4.488

View more
  12 in total

1.  Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients.

Authors:  Yang Wang; Yanna Liu; Hao Liao; Zhongping Deng; Dandan Bian; Yan Ren; Guangxin Yu; Yingying Jiang; Li Bai; Shuang Liu; Mei Liu; Li Zhou; Yu Chen; Xinyue Chen; Zhongping Duan; Fengmin Lu; Sujun Zheng
Journal:  Int J Med Sci       Date:  2022-05-09       Impact factor: 3.642

2.  Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients.

Authors:  Jun Li; Zhao Wu; Gui-Qiang Wang; Hong Zhao
Journal:  Chin Med J (Engl)       Date:  2021-03-17       Impact factor: 2.628

Review 3.  The Role of Hepatitis B Core-Related Antigen.

Authors:  Takako Inoue; Yasuhito Tanaka
Journal:  Genes (Basel)       Date:  2019-05-09       Impact factor: 4.096

Review 4.  Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection.

Authors:  Magda Rybicka; Krzysztof Piotr Bielawski
Journal:  Microorganisms       Date:  2020-09-15

Review 5.  Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis.

Authors:  Gian Paolo Caviglia; Angelo Armandi; Chiara Rosso; Davide Giuseppe Ribaldone; Rinaldo Pellicano; Sharmila Fagoonee
Journal:  Diagnostics (Basel)       Date:  2021-01-28

Review 6.  Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins.

Authors:  Sanae Hayashi; Katsuya Nagaoka; Yasuhito Tanaka
Journal:  Int J Mol Sci       Date:  2021-10-13       Impact factor: 5.923

7.  Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV.

Authors:  Chih-Wei Tseng; Wen-Chun Liu; Chi-Yi Chen; Ting-Tsung Chang; Kuo-Chih Tseng
Journal:  BMC Infect Dis       Date:  2022-04-09       Impact factor: 3.090

8.  Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients.

Authors:  Hao Liao; Le Li; Wei V Zheng; Jun Zou; Guangxin Yu; Lanlan Si; Feilin Ge; Tao Zhou; Dong Ji; Xiangmei Chen; Dongping Xu; Guanxun Cheng; Yan Liu; Junhui Chen
Journal:  Dis Markers       Date:  2022-07-14       Impact factor: 3.464

9.  Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss.

Authors:  I-Chin Wu; Wen-Chun Liu; Yen-Cheng Chiu; Hung-Chih Chiu; Pin-Nan Cheng; Ting-Tsung Chang
Journal:  Microorganisms       Date:  2021-05-26

10.  Circular RNA hsa_circ_0004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B.

Authors:  Liangdong Zhang; Zichao Wang
Journal:  Virol J       Date:  2020-03-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.